STOCK TITAN

VCXBU - $VCXBU STOCK NEWS

Welcome to our dedicated page for VCXBU news (Ticker: $VCXBU), a resource for investors and traders seeking the latest updates and insights on VCXBU stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VCXBU's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VCXBU's position in the market.

Rhea-AI Summary
10X Capital Venture Acquisition Corp. III (VCXB) received a notice from NYSE American regarding the late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The company's independent registered public accounting firm needed more time to review its financial statements. 10X III has a six-month Cure Period to file the report and regain compliance with NYSE American's listing standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
American Gene Technologies International Inc. (AGT) and 10X Capital Venture Acquisition Corp. III (VCXB) announced a merger agreement to form Addimmune, a publicly listed company focused on developing a functional cure for HIV. The investigational cell therapy, AGT103-T, has shown positive safety results in Phase I trials and will be targeted towards the 38 million people living with HIV globally. The proposed transaction represents a pre-money enterprise value of $500 million for Addimmune, with an additional earnout of up to $300 million tied to clinical and priced-based milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
VCXBU

NYSE:VCXBU

VCXBU Rankings

VCXBU Stock Data